For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Regulatory context
Regulatory context; not efficacy evidence
No matched controlled clinical study of this exact preparation was verified in this source audit.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Related-compound evidence is contextual only. Commercial names, modifications and routes do not establish clinical equivalence.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.
CARS exploratory randomized double-blind trial: 208 stroke patients randomized; 205 in primary efficacy analysis.
Reported findings. Day 90 arm-function changes were 30.7 versus 15.9 ARAT points. Unitless Mann–Whitney arm-function effect estimator 0.71, CI 0.63–0.79; not a population success rate.
Nonresponse. No observed neglect benefit; few affected participants.
Harms. Adverse events 69.2% versus 71.2%; serious events 3 versus 7, investigators judged unrelated. Active-arm serious events included peripheral ischemia, renal colic and myocardial infarction.
Limits. Exploratory study and rehabilitation co-intervention limit generalization. Supplier porcine-mixture/FPF1070 identity assertion does not verify catalog-stock equivalence.
Preparation: Standardized porcine Cerebrolysin; vendor CerebroNeurogen/FPF1070 equivalence unverified. Route: Intravenous alongside rehabilitation.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.
CASTA: 1070 acute ischemic stroke patients randomized double-blind.
Reported findings. Severe-stroke subgroup signals were post hoc, not the primary endpoint.
Nonresponse. No significant primary composite-endpoint difference.
Harms. Full outcome-paper adverse-event details unverified in accessible abstract; safety not inferred.
Limits. Post hoc subgroup findings do not supersede neutral primary endpoint. Full outcome-paper methods, funding and conflict disclosures unverified; publisher access failed.
Preparation: Medicinal Cerebrolysin; catalog CerebroNeurogen equivalence unverified. Route: Intravenous alongside aspirin; not isolated research-market mixture.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.